Comparison of self-expandable metallic stent placement followed by laparoscopic resection and elective laparoscopic surgery without stent placement for left-sided colon cancer

Tomoyuki Ueki | Toru Miyake | Masatsugu Kojima | Sachiko Kaida | Hiroya Iida | Tomoharu Shimizu | Masaji Tani

Department of Surgery, Shiga University of Medical Science, Shiga, Japan

Correspondence
Tomoyuki Ueki, Department of Surgery, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu-shi, Shiga, 520-2192, Japan.
Email: ueki@belle.shiga-med.ac.jp

Abstract

Aim: Self-expandable metallic stent (SEMS) placement for obstructive colon cancer is widely performed as a bridge to surgery (BTS) procedure before resection. This study aimed to investigate the surgical and oncological results of laparoscopic elective surgery with or without SEMS placement to assess the efficacy of SEMS placement as a BTS.

Methods: We retrospectively analyzed consecutive patients with stage II, III, and IV left-sided colon cancer who underwent elective laparoscopic resection between 2013 and 2019. All patients were divided into two groups: with and without SEMS placement.

Results: The SEMS group included 24 patients, whereas the non-SEMS group included 86 patients. The serum hemoglobin and albumin levels were lower ($P = .049$, $P = .03$), and the serum leukocyte and C-reactive protein levels were higher ($P < .0001$, $P = .022$) in the SEMS group. The tumor diameter and tumor circumferential rate were higher in the SEMS group (both $P < .0001$). No significant differences were observed in operation time, blood loss, postoperative complications, or postoperative hospital stay. After 1:1 propensity score matching, 15 patients in the SEMS group were compared with 15 patients in the non-SEMS group. The 3-year overall survival rates of the SEMS and non-SEMS groups were 87.5% and 88.9%, respectively ($P = .97$). The 3-year recurrence-free survival rates of the SEMS and non-SEMS groups were 58.2% and 81.7%, respectively ($P = .233$). No significant difference was found in the sites of recurrence.

Conclusion: The perioperative and long-term outcomes of SEMS placement as a BTS before laparoscopic resection could be acceptable compared with other elective laparoscopic operations without SEMS placement.
1 | INTRODUCTION

Acute colon obstruction caused by cancer has been reported to occur in up to 30% of patients and has been the main reason for emergency colonic surgery.1-3 Emergency surgery for acute obstruction due to colon cancer is associated with increased morbidity and mortality compared with elective surgery.4,5 Placement of a self-expandable metallic stent (SEMS) was introduced for the palliative care of acute colon obstruction in the 1990s and thereafter started to be used as a bridge to surgery (BTS) procedure.6-9 In Japan, SEMS placement became available as a procedure covered by the national health insurance system in 2012. SEMS placement enables the avoidance of emergency surgery and the preparation of patients for curative resection with more detailed preoperative examinations, including total colonoscopy.10 Furthermore, as SEMS placement provides a waiting time until surgery, patients can resume oral intake and undergo treatments for anemia and infection.11 Although several studies have reported acceptable short- and long-term outcomes of SEMS placement as a BTS,12-15 another study was suspended because of a higher 30-day complication rate with BTS than with emergency surgery.16 Furthermore, the cohorts in some randomized controlled trials included many cases of perforation associated with SEMS placement and technical failure.17,18 On the basis of these conflicting results, the previous European guidelines stated that SEMS placement was not indicated as a curative-intent approach but might be performed for a palliative intent.19 However, in the latest guidelines, SEMS placement as a BTS is recommended by another meta-analysis that showed no differences in 5-year overall survival, 5-year disease-free survival, or local recurrence rate.20,21 Accordingly, the benefit of SEMS placement as a BTS remains controversial. The aim of this study was to verify the short-term effectiveness and long-term oncological outcomes of SEMS placement as a BTS for obstructive colon cancer.

2 | METHODS

2.1 | Patients

We retrospectively analyzed 110 consecutive patients with stage II, III, and IV left-sided colon cancer with or without SEMS insertion at Shiga University of Medical Science Hospital between 2013 and 2019. In this study, patients whose tumor was located in the descending colon, sigmoid colon, and rectosigmoid colon were included, and those whose tumor was located in the splenic flexure were excluded. A total of 24 patients underwent SEMS insertion. The diagnosis of colon obstruction was made on the basis of the results of physical examination, contrast-enhanced computed tomography, and colonoscopy. To assess oral intake levels and obstructive symptoms before and after SEMS placement, we used the ColoRectal Obstruction Scoring System (CROSS) constructed by the Japan Colonic Stent Safe Procedure Research Group (JCSSPRG).22,23 The patients’ oral intake level was scored as follows: CROSS 0, requiring continuous decompression; CROSS 1, no oral intake; CROSS 2, liquid or enteral nutrient intake; CROSS 3, soft-solid, low-residue, and full diet with symptoms of stricture; or CROSS 4, soft-solid, low-residue, and full diet without symptoms of stricture. The decision of SEMS placement was made according to the patient’s obstructive symptoms or after a discussion between the surgeon and the gastroenterologist. During the study period, a preoperative complication related to SEMS insertion (colon perforation by a guidewire) occurred in one patient, which needed emergency open surgery. The case was excluded from this study, because it was included in the exclusion criteria described below. All patients underwent elective laparoscopic resection. Patients with benign disease, distant metastasis, palliative care, and emergency surgery were excluded. Experienced gastroenterologists performed endoscopic SEMS placement according to the JCSSPRG guidelines. Of the 110 patients, 61 (55.5%) were men and 49 (44.5%) were women. The mean age of the patients was 71 years (range, 38-87 years) and the median follow-up period was 30.5 months (range, 0.8-77.7 months). Postoperative complications were classified according to the Clavien-Dindo classification version 5.0.

2.2 | Statistical analysis

Quantitative variables are presented as median (range), and categorical variables are reported as absolute numbers and percentages. Quantitative variables were analyzed using Student’s t test. Categorical variables were compared using Pearson’s chi-square test. Survival curves were plotted according to the Kaplan-Meier method, and differences between survival distributions were assessed using the log-rank test. To reduce the effects of confounding factors in the two groups, propensity score matching was performed for overall survival (OS) and recurrence-free survival (RFS). Propensity scores were derived using the following variables: age, sex, tumor location, tumor depth, tumor diameter, pathological stage, and adjuvant chemotherapy. Subsequently, patients in the SEMS group were matched to patients in the non-SEMS group according to propensity scores. JMP software version 10 (SAS Institute Inc, Cary, NC, USA) was used for statistical analyses, and differences with P-values <.05 were considered significant.
3 | RESULTS

3.1 | Patient characteristics

The patient characteristics are summarized in Table 1. Of the patients, 24 underwent SEMS insertion and 86 did not. A WallFlex™ colonic stent (Boston Scientific Inc, USA) was inserted in three patients, and Niti-S™ (TaeWoong Medical Inc, Korea) was inserted in 21 patients. Age, sex, and preoperative tumor marker levels were comparable between the two groups. In the blood biochemical tests at the first visit, the serum hemoglobin and albumin levels were significantly lower (\( P < .0001 \), \( P = .049 \)), and the serum leukocyte and C-reactive protein (CRP) levels were significantly higher (\( P < .0001 \), \( P = .023 \)) in the SEMS group. However, after SEMS placement, no significant differences were found between the two groups in serum hemoglobin, albumin, leukocyte, or CRP levels (data not shown). The histopathological characteristics are summarized in Table 1. The tumor was located in the descending colon in six patients (5.5%), in the sigmoid colon in 59 patients (53.6%), and in the rectosigmoid colon in 45 patients (40.9%). Significant differences in tumor diameter and tumor circumferential rate were observed between the two groups (both \( P < .0001 \)). The patients’ oral intake levels were scored as CROSS 0 in eight patients (33.3%), CROSS 2 in four patients (16.7%), CROSS 3 in seven patients (29.2%), and CROSS 4 in five patients (20.8%). The median interval between SEMS placement and surgery was 21 days.

3.2 | Surgical outcomes

With respect to surgical outcomes, no differences were observed between the two groups, except for the surgical procedure and diverting stoma construction rate (\( P = .018 \), \( P < .0001 \); Table 2). As shown in Table 2, postoperative complications (Clavien-Dindo classification version 5.0 grade II or higher) were observed in four cases (16.7%) in the SEMS group and in 17 cases (19.8%) in the non-SEMS group (\( P = .733 \)). In the non-SEMS group, anastomotic leakage occurred in two of 86 patients (2.3%). All patients recovered with conservative treatment. Postoperative mortality was not observed in either group. The median postoperative hospital stay was 11 days in the SEMS group and 10 days in the non-SEMS group (\( P = .74 \)). In terms of adjuvant chemotherapy, the SEMS group had a relatively lower rate than the non-SEMS group, although the difference was not significant (\( P = .13 \)).

3.3 | Long-term outcomes

Among the pathological stage II and III patients in the two groups (SEMS group, \( n = 18 \); non-SEMS group, \( n = 73 \)), five in the SEMS group (27.8%) and 10 in the non-SEMS group (13.7%, \( P = .149 \)) experienced recurrence. In the SEMS group, the most common sites of recurrence were the cecum, colon, and sigmoid colon (40.9%). Significant differences in tumor diameter and tumor circumferential rate were observed between the two groups (both \( P < .0001 \)). The patients’ oral intake levels were scored as CROSS 0 in eight patients (33.3%), CROSS 2 in four patients (16.7%), CROSS 3 in seven patients (29.2%), and CROSS 4 in five patients (20.8%). The median interval between SEMS placement and surgery was 21 days.

### TABLE 1 Patients’ characteristics

|                        | SEMS (n = 24) | Non-SEMS (n = 86) | P value |
|------------------------|--------------|-------------------|---------|
| Age (year)\( ^a \)     | 75 (51-86)   | 71 (38-87)        | .922    |
| Gender (n (%))         |              |                   |         |
| Male                   | 14 (58.3%)   | 47 (54.7%)        | .748    |
| Female                 | 10 (41.7%)   | 39 (45.3%)        |         |
| Hemoglobin (g/dL) \(^a\) | 11.2 (6.7-14.4) | 12.1 (7.1-17.1) | .049    |
| Leukocyte (×10^9/μL) \(^a\) | 7.2 (2.8-18.7) | 5.65 (2.7-9.5) | <.0001  |
| CRP (mg/dL) \(^a\)     | 0.36 (0.02-20.88) | 0.18 (0-4.98) | .023    |
| Albumin (g/dL) \(^a\)  | 3.45 (2.6-4.4) | 3.7 (2.7-4.6) | .031    |
| CEA (ng/mL) \(^a\)     | 10.75 (0.5-213) | 5 (1-6922.1) | .675    |
| CA19-9 (U/ml) \(^a\)   | 19 (1-102)   | 16 (1-576)        | .615    |
| Tumor location (n (%)) |              |                   |         |
| Descending colon       | 2 (8.3%)     | 4 (4.7%)          | .189    |
| Sigmoid colon          | 16 (66.7%)   | 43 (50%)          |         |
| Rectosigmoid colon     | 6 (25%)      | 39 (45.3%)        |         |
| Tumor depth (n (%))    |              |                   |         |
| T3                     | 14 (58.3%)   | 62 (72.1%)        | .09     |
| T4a                    | 10 (41.7%)   | 19 (22.1%)        |         |
| T4b                    | 0 (0%)       | 5 (5.8%)          |         |
| Tumor diameter (mm) \(^a\) | 60 (29-84)   | 40 (15-95)        | <.0001  |
| Circumferential rate (%)\(^a\) | 100 (60-100) | 69.5 (19-100) | <.0001  |
| Harvested lymph nodes \(^a\) | 20 (11-44) | 20 (2-56) | .653    |
| Lymph node metastasis (n (%)) | | | |
| 0                      | 12 (50%)     | 40 (46.5%)        | .694    |
| 1                      | 6 (25%)      | 30 (34.9%)        |         |
| 2                      | 6 (25%)      | 15 (17.4%)        |         |
| 3                      | 0 (0%)       | 1 (1.2%)          |         |
| Histological differentiation (n (%)) | | | |
| Well                   | 3 (12.5%)    | 22 (25.6%)        | .58     |
| Moderate               | 19 (79.2%)   | 59 (68.6%)        |         |
| Poor/ mucinous         | 2 (8.3%)     | 5 (5.8%)          |         |
| Vascular invasion (n (%)) | | | |
| +                      | 19 (79.2%)   | 69 (80.2%)        | .91     |
| −                      | 5 (20.8%)    | 17 (19.8%)        |         |
| Lymphatic invasion (n (%)) | | | |
| +                      | 15 (62.5%)   | 51 (59.3%)        | .777    |
| −                      | 9 (37.5%)    | 35 (40.7%)        |         |

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; SEMS, self-expandable metallic stent.

\(^a\)Data are presented as median (range). \( P \)-values < .05 were considered significant.
TABLE 2  Surgical characteristics and outcomes

|                      | SEMS (n = 24) | Non-SEMS (n = 86) | P value |
|----------------------|---------------|-------------------|---------|
| Surgical procedure   |               |                   |         |
| Left hemicolecotomy  | 6 (25%)       | 5 (5.8%)          | .018    |
| Sigmoid colectomy    | 11 (45.8%)    | 35 (40.7%)        |         |
| High anterior resection | 6 (25%)     | 44 (51.2%)        |         |
| Hartmann's procedure | 1 (4.2%)      | 2 (2.3%)          |         |
| Diverting stoma      | 5 (21.7%)     | 1 (1.2%)          | .0001   |
| Operation time (min) | 232.5 (137-609) | 239 (134-498)   | .7      |
| Blood loss (g)       | 0 (0-489)     | 0 (0-556)         | .456    |
| Postoperative comp.  |               |                   |         |
| ≥ CD grade II (%)    |               |                   |         |
| +                    | 4 (16.7%)     | 17 (19.8%)        | .733    |
| -                    | 20 (83.3%)    | 69 (80.2%)        |         |
| Postoperative hospital stay (day) | 11 (8-19) | 10 (7-63) | .74 |
| Adjuvant chemotherapy |               |                   | .13     |
| +                    | 5 (27.8%)     | 35 (47.9%)        |         |
| -                    | 13 (72.2%)    | 38 (52.1%)        |         |

Abbreviations: CD, Clavien-Dindo classification; SEMS, self-expandable metallic stent.

aData are presented as median (range). P-values <.05 were considered significant.

recurrence were the liver (n = 2) and lymph node (n = 2), followed by the lung (n = 1). In the non-SEMS group, the most common recurrence patterns were recurrence in the liver (n = 4), followed by recurrence in the lung (n = 2), peritoneal seeding (n = 2), and local recurrence (n = 2). The sites of recurrence were not significantly different between the two groups (P = .199). To reduce the effects of confounding factors in the two groups, propensity score matching analysis was performed for OS and RFS. The following confounders were included in propensity score matching: age, sex, tumor location, tumor depth, tumor diameter, pathological stage, and adjuvant chemotherapy. Propensity score matching was conducted to match 15 patients in the SEMS group and 15 patients in the non-SEMS group in a 1:1 ratio. The characteristics of the matched cohorts are shown in Tables 3 and 4. After matching, no significant differences were noted between the two groups. The 3-year OS rate after matching was 87.5% in the SEMS group and 88.9% in the non-SEMS group (P = .97, Figure 1). The 3-year RFS rate after matching was 58.2% in the SEMS group and 81.7% in the non-SEMS group (P = .233, Figure 2).

4 | DISCUSSION

SEMS were originally used for the palliative care of patients with obstructive colon cancer in the 1990s.6,7 Thereafter, the use of SEMS gradually expanded to include decompression followed by curative resection as a BTS.8,9 In Japan, SEMS became available as a procedure covered by the national health insurance system in 2012. Tomita et al reported that SEMS placement as a BTS for obstructive

TABLE 3  Patients’ characteristics after propensity score matching

|                      | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|----------------------|---------------|-------------------|---------|
| Age (year)           | 70 (51-86)    | 74 (38-86)        | .709    |
| Gender (n%)          |               |                   |         |
| Male                 | 8 (53.3%)     | 9 (60%)           | .712    |
| Female               | 7 (46.7%)     | 6 (40%)           |         |
| Hemoglobin (g/dL)    | 11.7 (9.1-13.9) | 10.6 (7.1-14.4) | .227    |
| CRP (mg/dL)          | 0.24 (0.01-1.76) | 0.34 (0.03-1.47) | .599    |
| Albumin (g/dL)       | 3.4 (2.9-4.2) | 3.5 (2.8-4.3)     | .641    |
| CEA (ng/mL)          | 13.5 (5.0-195.9) | 5.7 (1.3-18.6) | .157    |
| CA19-9 (U/ml)        | 22.5 (1-102)  | 19 (5-38)         | .142    |
| Tumor location (n%)  |               |                   |         |
| Descending colon     | 0 (0%)        | 2 (13.3%)         | .335    |
| Sigmoid colon        | 11 (73.3%)    | 10 (66.7%)        |         |
| Rectosigmoid colon   | 4 (26.7%)     | 3 (20%)           |         |
| Tumor depth (n%)     |               |                   |         |
| T3                   | 11 (73.3%)    | 12 (80%)          | .666    |
| T4a                  | 4 (26.7%)     | 3 (20%)           |         |
| Tumor diameter (mm)  | 60 (29-70)    | 53 (40-70)        | .394    |
| Circumferential rate (%) | 100 (60-100) | 100 (49-100) | .104    |
| Harvested lymph nodes | 20 (12-44)  | 26 (10-41)        | .162    |
| Lymph node metastasis (n%) |     |                   |         |
| 0                    | 8 (53.3%)     | 9 (60%)           | .904    |
| 1                    | 3 (20%)       | 3 (20%)           |         |
| 2                    | 4 (26.7%)     | 3 (20%)           |         |
| Histological differentiation (n%) |     |                   |         |
| Well                 | 1 (6.7%)      | 4 (26.7%)         | .334    |
| Moderate             | 13 (86.6%)    | 10 (66.6%)        |         |
| Poor/ mucinous       | 1 (6.7%)      | 1 (6.7%)          |         |
| Vascular invasion (n%) |               |                   | .409    |
| +                    | 10 (66.7%)    | 12 (80%)          |         |
| -                    | 5 (33.3%)     | 3 (20%)           |         |
| Lymphatic invasion (n%) |               |                   | .439    |
| +                    | 9 (60%)       | 11 (73.3%)        |         |
| -                    | 6 (40%)       | 4 (26.7%)         |         |
| Stage (n%)           |               |                   | .712    |
| II                   | 8 (53.3%)     | 9 (60%)           |         |
| III                  | 7 (46.7%)     | 6 (40%)           |         |

Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reactive protein; SEMS, self-expandable metallic stent.

aData are presented as median (range). P-values <.05 were considered significant.
colorectal cancer was safe and effective with low morbidity, low mortality, and a low stoma construction rate, in their analysis of two multicenter prospective feasibility studies. Other previous studies also reported that SEMS placement was associated with tolerable surgical outcomes compared with transanal decompression tube insertion and diverting ileostomy creation. Furthermore, the improvement of bowel obstruction by SEMS placement has been suggested to contribute to the conversion of emergency surgery cases to elective surgery cases. This advantage has enabled patients to undergo more detailed preoperative examinations and to resume oral intake before curative resection. Our study found no differences in operation time, blood loss, postoperative complications, or postoperative hospital stay between the SEMS and non-SEMS groups. These perioperative outcomes were equivalent to those reported in several previous studies. However, in the blood biochemical tests at the first visit, the serum hemoglobin and albumin levels were significantly lower, and the serum leukocyte and CRP levels were significantly higher in the SEMS group than in the non-SEMS group. Although obstructive colon cancer can worsen the patients’ general condition, no significant differences were found between the two groups in serum hemoglobin, albumin, leukocyte, or CRP levels after SEMS placement. The improved general

| Surgical procedure (n (%)) | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|---------------------------|--------------|------------------|--------|
| Left hemi-colectomy       | 4 (26.7%)    | 2 (13.3%)        | .656   |
| Sigmoid colectomy         | 7 (46.6%)    | 8 (53.3%)        |        |
| High anterior resection   | 4 (26.7%)    | 5 (33.4%)        |        |
| Diverting stoma constructed after resection (n (%)) | 2 (13.3%) | 0 (0%) | .143 |

| Operation time (minute) | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|-------------------------|--------------|------------------|--------|
|                         | 233 (137-409) | 233 (140-349)    | .538   |

| Blood loss (g) | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|----------------|--------------|------------------|--------|
| 0 (0-450)     | 0 (0-556)    | .789             |

| Postoperative complication, ≥CD grade II (n (%)) | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|-------------------------------------------------|--------------|------------------|--------|
| +                                               | 3 (20%)      | 5 (33.3%)        | .409   |
| -                                               | 12 (80%)     | 10 (66.7%)       |        |

| Postoperative hospital stay (day) | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|----------------------------------|--------------|------------------|--------|
| 10 (9-18)                        |              | 9 (7-18)         | .157   |

| Adjuvant chemotherapy (n (%))     | SEMS (n = 15) | Non-SEMS (n = 15) | P value |
|----------------------------------|--------------|------------------|--------|
| +                                | 5 (33.3%)    | 4 (26.7%)        | .69    |
| -                                | 10 (66.7%)   | 11 (73.3%)       |        |

Abbreviations: CD, Clavien-Dindo classification; SEMS, self-expandable metallic stent.

*aData are presented as median (range). P-values <.05 were considered significant.

**FIGURE 1** Overall survival of 30 pathological stage II and III colon cancer patients with and without SEMS placement after propensity score matching. SEMS, self-expandable metallic stent.
conditions after SEMS placement in the SEMS group may have led to perioperative outcomes comparable to those of the non-SEMS group. However, patients in the SEMS group more frequently underwent diverting ileostomy creation in this study. A possibility exists that a diverting stoma was constructed in the SEMS group according to the surgeon’s decision to prevent serious conditions in case of anastomotic leakage. However, although acceptable short-term outcomes of SEMS as a BTS have been reported, the long-term oncological outcomes remain controversial. Several studies have been conducted on the detrimental effects of SEMS placement on long-term outcomes.26-28 Takahashi et al reported that SEMS placement leads to increased circulating tumor DNA levels and the possibility of increased recurrence.29 However, several studies, including randomized control studies, have reported acceptable long-term outcomes of SEMS as a BTS.30,31 In the study by Sato et al, the 3-year OS and disease-free survival rates were comparable between the SEMS group and the transanal decompression tube group.22 Moreover, recent meta-analyses have reported no difference in long-term outcomes and no differences in distant or local recurrence rates between BTS and emergency surgery.3,32 In this study, we performed propensity score matching analysis with respect to long-term outcomes. No significant difference in OS or RFS was observed between the SEMS group and the transanal decompression tube group.22 Therefore, SEMS placement followed by laparoscopic resection was considered to have acceptable results compared with other elective laparoscopic operations without SEMS placement. Furthermore, the recurrence pattern was not significantly different between the two groups, as in previous reports.22,32

Our study had several limitations. First, this study had a retrospective design and was performed at a single institution. Second, the sample size was small. Third, the indications of SEMS placement for obstructive colon cancer were unclear. In fact, several patients in the SEMS group had no obstructive symptoms. Moreover, the median follow-up period was relatively short, and the observation period differed between the two groups (median 26.8 and 32.7 months). We expect that prospective multicenter studies with larger sample sizes will verify our results in the future. In conclusion, despite the above-mentioned limitations, the perioperative and long-term outcomes of SEMS placement as a BTS before laparoscopic resection may be acceptable in comparison with other elective laparoscopic operations without SEMS placement. SEMS placement seems to be useful as a preoperative decompression modality for left-sided obstructive colon cancer.

CONFLICT OF INTEREST
The authors declare no conflict of interests for this article.

ETHICAL STATEMENT
The protocol for this research project was approved by the Ethics Committee of the institution (R2017-271) and it conforms to the provisions of the Declaration of Helsinki.

ORCID
Tomoyuki Ueki https://orcid.org/0000-0002-7285-5222
Hiroya Iida https://orcid.org/0000-0001-6245-4583
Tomoharu Shimizu https://orcid.org/0000-0002-2858-0786

REFERENCES
1. Gorissen KJ, Tuynman JB, Fryer E, Wang L, Uboeri R, Jones OM, et al. Local recurrence after stenting for obstructing left-sided colonic cancer. Br J Surg. 2013;100:1805–9.
2. McCullough JA, Engledow AH. Treatment options in obstructed left-sided colonic cancer. Clin Oncol. 2010;22:764–70.
3. Matsuda A, Miyashita M, Matsumoto S, Matsutani T, Sakurazawa N, Takahashi G, et al. Comparison of long-term outcomes of colonic stent as “bridge to surgery” and emergency surgery for malignant large-bowel obstruction: a meta-analysis. Ann Surg Oncol. 2015;22:497–504.
4. Barillari P, Aurello P, De Angelis R, Valabrega S, Ramacciato G, D’Angelo F, et al. Management and survival of patients
affected with obstructive colorectal cancer. Int Surg. 1992;77: 251–5.

5. De Ceglie A, Filliberti R, Baron TH, Ceppi M, Conio M. A meta-analysis of endoscopic stenting as bridge to surgery versus emergency surgery for left-sided colorectal cancer obstruction. Crit Rev Oncol Hematol. 2013;88:387–403.

6. Itabashi M, Hamano K, Kameoka S, Asahina K. Self-expanding stainless steel stent application in rectosigmoid stricture. Dis Colon Rectum. 1993;36:508–11.

7. Dohmoto M, Hunerbein M, Schlag PM. Application of rectal stents for palliation of obstructing rectosigmoid cancer. Surg Endosc. 1997;11:758–61.

8. Tejero E, Mainar A, Fernandez L, Tobio R, De Gregorio MA. New procedure for the treatment of colorectal neoplastic obstructions. Dis Colon Rectum. 1994;37:1158–9.

9. Saida Y, Sumiyama Y, Nagao J, Takase M. Stent endoprosthesis for obstructing colorectal cancers. Dis Colon Rectum. 1996;39: 552–5.

10. Tomita M, Saito S, Makimoto S, Koizumi K, Saida Y. Self-expandable metallic stenting as a bridge to surgery for malignant colorectal obstruction: pooled analysis of 426 patients from two prospective multicenter series. Surg Endosc. 2019;33:499–509.

11. Adler DG. Management of malignant colonic obstruction. Curr Treat Options Gastroenterol. 2005;8:231–7.

12. Saida Y, Sumiyama Y, Nagao J, Uramatsu M, et al. Long-term prognosis of preoperative “bridge to surgery” expandable metallic stent insertion for obstructive colorectal cancer: comparison with emergency operation. Dis Colon Rectum. 2003;46:544–549.

13. Zhao XD, Cai BB, Cao RS, Shi RH. Palliative treatment for incurable malignant colorectal obstructions: a meta-analysis. World J Gastroenterol. 2013;19:5565–74.

14. Cicorci R, Farinella E, Trastulli S, Desiderio J, Listorti C, Boselli C, et al. Safety and efficacy of endoscopic colorectal stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2013;22:14–21.

15. Liang TW, Sun Y, Wei YC, Yang D-X. Palliative treatment of malignant colorectal obstruction caused by advanced malignancy: a self-expanding metallic stent or surgery? A system review and meta-analysis. Surg Today. 2014;44:22–33.

16. van Hooft JE, Bemelman WA, Oldenburg B, Marinelli AW, Holzik MFL, Grubben MJ. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol. 2011;12:344–52.

17. Pirlet IA, Slim K, Kwiatkowski F, Michot F, Millat BL. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic obstruction: a multicenter randomized controlled trial. Surg Endosc. 2011;25:1814–21.

18. Ho KS, Quah HM, Lim JF, Tang C-L, Eu K-W. Endoscopic stenting and elective surgery versus emergency surgery for left-sided malignant colonic obstruction: a prospective randomized trial. Int J Colorectal Dis. 2012;27:355–62.

19. van Hooft JE, van Halsema EE, Vanbiervliet G, Beets-Tan R, DeWitt J, Donnellen F, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2014;46:990–1005.

20. Amelung FJ, Burghgraef TA, Tanis PJ, van Hooft JE, ter Borg F, Siersema PD, et al. Critical appraisal of oncological safety of stent as bridge to surgery in left-sided obstructing colon cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;131:66–75.

21. van Hooft JE, van Halsema EE, Vanbiervliet G, Beets-Tan RGH, Everett S, Götz M, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Update 2020. Endoscopy. 2020;52:389–407.

22. Matsuzawa T, Ishida H, Yoshida S, Isayama H, Kuwai T, Maetani I, et al. A Japanese prospective multicenter study of self-expandable metal stent placement for malignant colorectal obstruction: short-term safety and efficacy within 7 days of stent procedure in 513 cases. Gastrointest Endosc. 2015;82:697–707.

23. Saito S, Yoshida S, Isayama H, Matsuzawa T, Kuwai T, Maetani I, et al. A prospective multicenter study on self-expandable metallic stents as a bridge to surgery for malignant colorectal obstruction in Japan: efficacy and safety in 312 patients. Surg Endosc. 2016;30:3976–86.

24. Sato R, Oikawa M, Ito K, Tsuchiya T. Comparison of the long-term outcomes of the self-expandable metallic stent and transanal decompression tube for obstructive colorectal cancer. Ann Gastroenterol Surg. 2019;3:209–16.

25. Diane M, Charles S, Mehdi K. What is the best option between primary diverting stoma and endoscopic stent as a bridge to surgery with a curative intent for obstructed left colon cancer? Results from a propensity score analysis of the French Surgical Association Multicenter Cohort of 518 patients. Ann Surg Oncol. 2019;26:756–64.

26. Sabbagh C, Brouet F, Diouf M, Cosse C, Brehant O, Bartoli E, et al. Is stenting as ‘a bridge to surgery’, an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. Ann Surg. 2013;258:107–15.

27. Kim HJ, Choi GS, Park JS, Park SY, Jun SH. Higher rate of perineural invasion in stent-laparoscopic approach in comparison to emergent open resection for obstructing left-sided colon cancer. Int J Colorectal Dis. 2013;28:407–14.

28. Sloothaak DA, van den Berg MW, Dijkgraaf MG, Fockens P, Tanis PJ, van Hooft JE, et al. Oncological outcome of malignant colonic obstruction in the Dutch Stent-In 2 trial. Br J Surg. 2014;101: 1751–7.

29. Takahashi G, Yamada T, Uehida E. Oncological assessment of stent placement for obstructive colorectal cancer from circulating cell-free DNA and circulating tumor DNA dynamics. Ann Surg Oncol. 2018;25:737–44.

30. Amelung FJ, Borg F, Consten EC, Siersema PD, Draaisma WA. Deviating colostomy construction versus stent placement as bridge to surgery for malignant left-sided colonic obstruction. Surg Endosc. 2016;30:5345–55.

31. Arezzo A, Balague C, Targarona E, Borghi F, Giraudo G, Ghezzo L, et al. Colonic stenting as a bridge to surgery versus emergency surgery for malignant colonic obstruction: results of a multicentre randomised controlled trial (ESCO trial). Surg Endosc. 2018;32(8):3297–305.

32. Ceresoli M, Allievi N, Coccolini F, Montori G, Fugazzola P, Pisano M, et al. Long-term oncologic outcomes of stent as a bridge to surgery versus emergency surgery in malignant left side colonic obstructions: a meta-analysis. J Gastrointest Oncol. 2017;8: 867–76.